Codexis Stock News

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Codexis (NASDAQ:CDXS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Code

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Codexis (CDXS – Research Report) today and set a price

Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announce a par

Has the next biotech unicorn just been minted? Two California firms are focused on a radical new way of writing DNA to create everything from COVID-19 antibodies to high-density data storage.

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev

Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS,

The

Q1 2020 Codexis Inc Earnings Call

Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metaboli

REDWOOD CITY, Calif., May 27, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment.